If you join this session you will receive:
The weblink, call details and agenda before the event.
2.0 CE CREDITS on completion of a brief online post-session quiz (except in Alberta).
AGENDA
Chair and Moderator
Denise Balch, President, Connex Health
Migraine in the Workplace: The Burden, the Impact and the Solution
Dr. Christine Lay, MD, FRCP, FAHS, Neurologist, Women’s College Hospital
Dr. Lay will review the economic and personal costs of undiagnosed and poorly managed migraine in the workplace, as well as ways to reduce stigma, absenteeism and presenteeism with cost-saving solutions.
Stressors and Coping Strategies
Jamie Marcellus, RN, MBA, President, Humanacare
Jamie will share EAP utilization trends and how those have changed since COVID-19. He will also address coping strategies that are not constructive and the EAP interventions they require.
Workplace Impact
Mike Mousseau, PhD, National Wellbeing and Engagement Consultant, Gallagher Benefit Services
Dr. Mousseau will speak to the personal and workplace impact of pain management and how organizational culture can influence behaviours.
Panel Discussion
Join our panel to take your questions and discuss the challenges of pain management and the challenges of successfully living and working in today’s environment.
Registration discount of $25.00 if you are a member of the Connex Canadian Benefits Network (CCBN). All are welcome to join for access to our blogs, podcasts, resource library and ask the expert forum.
Registration Fees: $50.00 plus HST. Refunds available up to 48 hours before the event, subject to $10.00 processing fee.
Thank you to our Benefits Breakfast Club (BBC) sponsors for their support during COVID-19. Thank you to national sponsors – Allergan, a division of Abbvie for sponsoring Dr. Lay’s presentation and our other sponsors for this season: Abbvie, AMGEN, Astra Zeneca, GSK, Janssen Inc., Novartis, Novo Nordisk and Roche.
As well as regional sponsors – Abbott and Sobeys/MHCSI.
Plus national emerging sponsors – Canadian Association of Optometrists, Innovative Medicines Canada and Gilead.
